Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California.
| Revenue (Most Recent Fiscal Year) | $196.54M |
| Net Income (Most Recent Fiscal Year) | $-140.04M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 12.01 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 24.15 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -13.62% |
| Net Margin (Trailing 12 Months) | -13.94% |
| Return on Equity (Trailing 12 Months) | -29.69% |
| Return on Assets (Trailing 12 Months) | -12.52% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.50 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.28 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.68 |
| Inventory Turnover (Trailing 12 Months) | 1.83 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.35 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.06 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.16 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.36 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 122.49M |
| Free Float | 110.98M |
| Market Capitalization | $3.82B |
| Average Volume (Last 20 Days) | 2.40M |
| Beta (Past 60 Months) | 1.69 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.40% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |